- Home
- AMLX vs CRVS Comparison
AMLX vs CRVS Comparison
Compare AMLX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- CRVS
- Stock Information
- Founded
- AMLX 2014
- CRVS 2014
- Country
- AMLX United States
- CRVS United States
- Employees
- AMLX N/A
- CRVS N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- CRVS Health Care
- Exchange
- AMLX Nasdaq
- CRVS Nasdaq
- Market Cap
- AMLX 481.9M
- CRVS 516.0M
- IPO Year
- AMLX 2022
- CRVS 2016
- Fundamental
- Price
- AMLX $4.05
- CRVS $4.99
- Analyst Decision
- AMLX Buy
- CRVS Buy
- Analyst Count
- AMLX 7
- CRVS 4
- Target Price
- AMLX $7.60
- CRVS $12.83
- AVG Volume (30 Days)
- AMLX 786.1K
- CRVS 1.6M
- Earning Date
- AMLX 11-07-2024
- CRVS 11-12-2024
- Dividend Yield
- AMLX N/A
- CRVS N/A
- EPS Growth
- AMLX N/A
- CRVS N/A
- EPS
- AMLX N/A
- CRVS N/A
- Revenue
- AMLX $196,485,000.00
- CRVS N/A
- Revenue This Year
- AMLX N/A
- CRVS N/A
- Revenue Next Year
- AMLX N/A
- CRVS N/A
- P/E Ratio
- AMLX N/A
- CRVS N/A
- Revenue Growth
- AMLX N/A
- CRVS N/A
- 52 Week Low
- AMLX $1.58
- CRVS $1.30
- 52 Week High
- AMLX $19.95
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AMLX 36.50
- CRVS 28.00
- Support Level
- AMLX $3.78
- CRVS $3.77
- Resistance Level
- AMLX $4.40
- CRVS $7.44
- Average True Range (ATR)
- AMLX 0.30
- CRVS 0.60
- MACD
- AMLX -0.12
- CRVS -0.41
- Stochastic Oscillator
- AMLX 15.52
- CRVS 25.85
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).